Adding a probiotic to a gut-targeting biologic therapy for moderate bowel inflammation

This trial is testing whether combining a probiotic supplement called VSL#3 with vedolizumab—a medication that targets the immune system in the gut—works better than vedolizumab alone for treating moderate ulcerative colitis. Half of the participants will receive the probiotic along with the medication, while the other half will receive a placebo (inactive powder) with the same medication. Researchers want to see if the probiotic helps reduce inflammation and improve symptoms faster.

Vedolizumab is already an effective treatment for ulcerative colitis, but not everyone responds well to it alone. This study is exploring whether adding a probiotic—which may help restore healthy bacteria in the gut—can make the treatment work even better for people whose disease hasn't improved with standard therapies.